NASDAQ · IMMX
Immix Biopharma, Inc.
$7.98-$0.15 (-1.78%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.15% below the high.
Loading market information…
NASDAQ · TLSA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Tiziana Life Sciences Ltd’s quoted price sits in the lower half of its reported 52-week range, 53.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tiziana Life Sciences Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.98-$0.15 (-1.78%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.15% below the high.
$3.30-$0.16 (-4.62%)
Whitehawk Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$1.99-$0.07 (-3.4%)
Zentalis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.37% below the high.
$3.98-$0.08 (-1.97%)
Coya Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.88% below the high.
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
$0.86-$0.03 (-3.35%)
Pliant Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.75% below the high.
$4.11-$0.12 (-2.72%)
eXoZymes, Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.66% below the high.
